UY39561A - Inhibidores de IRAK4 - Google Patents

Inhibidores de IRAK4

Info

Publication number
UY39561A
UY39561A UY0001039561A UY39561A UY39561A UY 39561 A UY39561 A UY 39561A UY 0001039561 A UY0001039561 A UY 0001039561A UY 39561 A UY39561 A UY 39561A UY 39561 A UY39561 A UY 39561A
Authority
UY
Uruguay
Prior art keywords
irak4 inhibitors
irak4
medicine
consequently
formula
Prior art date
Application number
UY0001039561A
Other languages
English (en)
Spanish (es)
Inventor
Ina Terstiege
Stefan Schiesser
Yafeng Xue
Chang Hui-Fang
Ingrid Kristina Berggren Anna
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY39561A publication Critical patent/UY39561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001039561A 2020-12-10 2021-12-10 Inhibidores de IRAK4 UY39561A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063199160P 2020-12-10 2020-12-10

Publications (1)

Publication Number Publication Date
UY39561A true UY39561A (es) 2022-06-30

Family

ID=79230946

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039561A UY39561A (es) 2020-12-10 2021-12-10 Inhibidores de IRAK4

Country Status (33)

Country Link
US (3) US11866405B2 (cg-RX-API-DMAC7.html)
EP (1) EP4259632B1 (cg-RX-API-DMAC7.html)
JP (1) JP7749015B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118153A (cg-RX-API-DMAC7.html)
CN (1) CN116583285B (cg-RX-API-DMAC7.html)
AR (1) AR124303A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021395816B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203569A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001662A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007624A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230264A (cg-RX-API-DMAC7.html)
DK (1) DK4259632T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000119A (cg-RX-API-DMAC7.html)
EC (1) ECSP23050553A (cg-RX-API-DMAC7.html)
ES (1) ES2989489T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259632T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241312T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068584T2 (cg-RX-API-DMAC7.html)
IL (1) IL303356B2 (cg-RX-API-DMAC7.html)
LT (1) LT4259632T (cg-RX-API-DMAC7.html)
MA (1) MA62535B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006816A (cg-RX-API-DMAC7.html)
PE (1) PE20240684A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259632T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259632T (cg-RX-API-DMAC7.html)
RS (1) RS66095B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259632T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400417T1 (cg-RX-API-DMAC7.html)
TW (1) TWI902994B (cg-RX-API-DMAC7.html)
UA (1) UA130417C2 (cg-RX-API-DMAC7.html)
UY (1) UY39561A (cg-RX-API-DMAC7.html)
WO (1) WO2022122876A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306848B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152349A1 (en) * 2022-02-14 2023-08-17 Astrazeneca Ab Irak4 inhibitors
US20250326757A1 (en) * 2022-05-26 2025-10-23 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
HUE029617T2 (en) 2010-12-20 2017-03-28 Merck Serono Sa Indazolyl triazole derivatives as IRAK inhibitors
BG111378A (bg) * 2013-01-14 2015-01-30 Николай Цветков Субституирани индазолови производни като in-vitro mao-b инхибитори
RU2665554C2 (ru) * 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA2992406A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CN105503863A (zh) * 2015-12-11 2016-04-20 南京华威医药科技开发有限公司 新型抗肿瘤化合物
EP3394066A2 (en) 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
WO2017207386A1 (de) 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
JP2020524692A (ja) 2017-06-21 2020-08-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Irak4調節因子としてのベンゾフラン
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
KR20220027196A (ko) 2019-06-27 2022-03-07 바이오젠 엠에이 인코포레이티드 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
CN114585609B (zh) 2019-06-27 2024-07-30 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途

Also Published As

Publication number Publication date
DK4259632T3 (da) 2024-10-21
UA130417C2 (uk) 2026-02-11
IL303356B1 (en) 2026-04-01
HRP20241312T1 (hr) 2024-12-20
LT4259632T (lt) 2024-10-10
EP4259632B1 (en) 2024-07-24
PE20240684A1 (es) 2024-04-10
PT4259632T (pt) 2024-10-24
CL2023001662A1 (es) 2024-01-12
JP7749015B2 (ja) 2025-10-03
KR20230118153A (ko) 2023-08-10
ES2989489T3 (es) 2024-11-26
AU2021395816B2 (en) 2024-04-04
WO2022122876A1 (en) 2022-06-16
AR124303A1 (es) 2023-03-15
US20220185817A1 (en) 2022-06-16
AU2021395816A9 (en) 2025-03-13
ZA202306848B (en) 2024-04-24
CN116583285A (zh) 2023-08-11
IL303356A (en) 2023-08-01
HUE068584T2 (hu) 2025-01-28
FI4259632T3 (fi) 2024-10-24
TW202237612A (zh) 2022-10-01
EP4259632A1 (en) 2023-10-18
US11866405B2 (en) 2024-01-09
MX2023006816A (es) 2023-06-21
RS66095B1 (sr) 2024-11-29
ECSP23050553A (es) 2023-08-31
US20240182479A1 (en) 2024-06-06
MA62535B1 (fr) 2024-11-29
CA3203569A1 (en) 2022-06-16
US20260092069A1 (en) 2026-04-02
CR20230264A (es) 2023-07-26
SI4259632T1 (sl) 2024-12-31
IL303356B2 (en) 2026-08-01
CO2023007624A2 (es) 2023-06-30
PL4259632T3 (pl) 2024-12-16
SMT202400417T1 (it) 2024-11-15
CN116583285B (zh) 2026-03-24
US12448385B2 (en) 2025-10-21
TWI902994B (zh) 2025-11-01
AU2021395816A1 (en) 2023-07-13
DOP2023000119A (es) 2023-07-09
JP2023552838A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
CL2024002023A1 (es) Inhibidor del inflamosoma nlrp3 y uso del mismo
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
CO2024003923A2 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MX2021009276A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
NO20061432L (no) N3 alkylerte benzimidazolederivater som MEK-inhibitorer
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
MX2012014387A (es) Dispersiones solidas que contienen inhibidores de cinasa.
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
UY30440A1 (es) Nuevos compuestos
CN109563060A (zh) Ido1抑制剂及其制备方法和应用
PE20110943A1 (es) Formulacion oral solida de alisquireno
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CO2024012172A2 (es) Inhibidores de irak4
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY30289A1 (es) Derivados de la 1h-pirrol-3-carboxamida sustituida con 1-(tetrahidro-2h-piran-4-il-metil)-1h-bencimidazol, composiciones conteniéndolos, procedimientos de preparacion y aplicaciones
MX2023014722A (es) Forma cristalina de tolebrutinib y método de preparación y su uso.
CY1118398T1 (el) Δευτεριωμενη ενωση βενζοπυρανιου και χρηση αυτης
MX2024002552A (es) Inhibidor del antigeno de membrana prostatica especifico y uso farmaceutico del mismo.
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
PY2085970A (es) Compuestos químicos
UY39588A (es) Pirazolotiazol carboxamidas y usos de estas como inhibidores de pdgfr